SEARCH

SEARCH BY CITATION

References

  • 1
    Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med 2005; 353: 171123.
  • 2
    Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006; 147(Suppl. 1): S25868.
  • 3
    Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117: 52243.
  • 4
    Sellin JH, DeSoignie RC. Methylprednisolone increases absorptive capacity of rabbit ileum in vitro. Am J Physiol 1983; 245: G5627.
  • 5
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979; 77: 84769.
  • 6
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 7
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35: 3602.
  • 8
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 25560.
  • 9
    Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 31930.
  • 10
    Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1093100.
  • 11
    Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn’s disease? Aliment Pharmacol Ther 2002; 16: 85767.
  • 12
    Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 95663.
  • 13
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 1522.
  • 14
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2000; 2: CD000545.
  • 15
    Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2001; 3: CD000542.
  • 16
    Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 2000; 31: 815.
  • 17
    Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 32832.
  • 18
    Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353: 191225.
  • 19
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 20
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006; 63: 43342.
  • 21
    D’Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 66771.
  • 22
    Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4: 74453.
  • 23
    Berni CR, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis 2006; 38: 3817.
  • 24
    Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 8118.
  • 25
    Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl. 1): i1635.
  • 26
    Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(Suppl. 5): V116.
  • 27
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 94087.
  • 28
    Binder HJ. Pathophysiological approach to treatment of diarrhea in Crohn’s disease. In: IrvingP, RamptonD, ShanahanF, eds. Clinical Dilemmas in Inflammatory Bowel Disease. Oxford: Blackwell Publishing, 2006: 16870.
  • 29
    Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut 2006; 55(Suppl. 1): i3658.
  • 30
    Jones JH, Lennard-Jones JE. Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut 1966; 7: 1817.
  • 31
    Sparberg M, Kirsner JB. Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 1966; 11: 86580.
  • 32
    Wheeler SC, Marion JF, Present DH. Medical therapy, not surgery is the appropriate first line treatment for Crohn’s enterovesical fistula. Gastroenterology 1998; 114: A1113.
  • 33
    Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2003; 4: CD000301.
  • 34
    Brignola C, Campieri M, Farruggia P, et al. The possible utility of steroids in the prevention of relapses of Crohn’s disease in remission. A preliminary study. J Clin Gastroenterol 1988; 10: 6314.
  • 35
    Ferguson A, Campieri M, Doe W, Persson T, Nygard G. Oral budesonide as maintenance therapy in Crohn’s disease–results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12: 17583.
  • 36
    Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 36371.
  • 37
    Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100: 17807.
    Direct Link:
  • 38
    Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn’s disease activity index are associated with corticosteroid resistance in active Crohn’s disease. Am J Gastroenterol 2002; 97: 143845.
    Direct Link:
  • 39
    Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol 1998; 10: 8215.
  • 40
    Brignola C, De Simone G, Belloli C, et al. Steroid treatment in active Crohn’s disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994; 8: 4658.
  • 41
    Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 83641.
  • 42
    Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002; 97: 174854.
    Direct Link:
  • 43
    Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339: 3704.
  • 44
    Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994; 331: 8425.
  • 45
    Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997; 41: 20914.
  • 46
    Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996; 8: 9059.
  • 47
    Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115: 83540.
  • 48
    Escher JC. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16: 4754.
  • 49
    Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2005; 4: CD000296.
  • 50
    McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs 2002; 62: 226382.
  • 51
    Chun A, Chadi RM, Korelitz BI, et al. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn’s disease: a randomized double-blind study and follow-up. Inflamm Bowel Dis 1998; 4: 17781.
  • 52
    Levin TL, Morton E. Adrenal hemorrhage complicating ACTH therapy in Crohn’s disease. Pediatr Radiol 1993; 23: 4578.
  • 53
    Korelitz BI. Steroids for Crohn’s disease–an appreciation and a vote of confidence. Inflamm Bowel Dis 2002; 8: 21922.
  • 54
    Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978; 16: 23855.
  • 55
    Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn’s disease. J Clin Gastroenterol 1986; 8: 1549.
  • 56
    Berghouse LM, Elliott PR, Lennard-Jones JE, English J, Marks V. Plasma prednisolone levels during intravenous therapy in acute colitis. Gut 1982; 23: 9803.
  • 57
    Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007; 102: 6018.
    Direct Link:
  • 58
    Tromm A, Mollmann H, Barth J, et al. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol 2001; 41: 53641.
  • 59
    Lima JJ, Giller J, Mackichan JJ, Jusko WJ. Bioavailability of hydrocortisone retention enemas in normal subjects. Am J Gastroenterol 1980; 73: 2327.
  • 60
    Petitjean O, Wendling JL, Tod M, et al. Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. Aliment Pharmacol Ther 1992; 6: 3517.
  • 61
    Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M, Derendorf H. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate. J Pharm Sci 1991; 80: 8356.
  • 62
    Luman W, Gray RS, Pendek R, Palmer KR. Prednisolone metasulphobenzoate foam retention enemas suppress the hypothalamo-pituitary-adrenal axis. Aliment Pharmacol Ther 1994; 8: 2558.
  • 63
    Tsuruoka S, Sugimoto K, Fujimura A. Drug-induced Cushing syndrome in a patient with ulcerative colitis after betamethasone enema: evaluation of plasma drug concentration. Ther Drug Monit 1998; 20: 3879.
  • 64
    Braverman DL, Lachmann EA, Nagler W. Avascular necrosis of bilateral knees secondary to corticosteroid enemas. Arch Phys Med Rehabil 1998; 79: 44952.
  • 65
    Barlow AD, Clarke GA, Kelly MJ. Acute adrenal crisis in a patient treated with rectal steroids. Colorectal Dis 2004; 6: 624.
  • 66
    De Boer AG, Moolenaar F, De Leede LG, Breimer DD. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7: 285311.
  • 67
    Shaffer JA, Williams SE, Turnberg LA, Houston JB, Rowland M. Absorption of prednisolone in patients with Crohn’s disease. Gut 1983; 24: 1826.
  • 68
    Rodrigues CA, Nabi EM, Spiliadis C, et al. Prednisolone absorption in inflammatory bowel disease: correlation with anatomical site and extent. Aliment Pharmacol Ther 1987; 1: 3919.
  • 69
    Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 2001; 15: 151525.
  • 70
    Klingenstein G, Levy RN, Kornbluth A, Shah AK, Present DH. Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther 2005; 21: 2439.
  • 71
    Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn’s disease: a population-based case control study. Inflamm Bowel Dis 2005; 11: 32530.
  • 72
    Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 4250.
  • 73
    Tobias JH, Sasi MR, Greenwood R, Probert CS. Rapid hip bone loss in active Crohn’s disease patients receiving short-term corticosteroid therapy. Aliment Pharmacol Ther 2004; 20: 9517.
  • 74
    Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 87883.
    Direct Link:
  • 75
    Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995; 57: 1159.
  • 76
    Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000; 11: 63759.
  • 77
    Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 20011.
  • 78
    Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 35264.
  • 79
    Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 1981; 24: 8928.
  • 80
    Freeman HJ, Kwan WC. Brief report: non-corticosteroid-associated osteonecrosis of the femoral heads in two patients with inflammatory bowel disease. N Engl J Med 1993; 329: 13146.
  • 81
    Vakil N, Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 1989; 96: 627.
  • 82
    Keenan GF. Management of complications of glucocorticoid therapy. Clin Chest Med 1997; 18: 50720.
  • 83
    Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 95463.
  • 84
    Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 3207.
  • 85
    Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn’s disease. Clin Gastroenterol Hepatol 2005; 3: 121520.
  • 86
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 62130.
  • 87
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 236876.
  • 88
    Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut 1993; 34: 93943.
  • 89
    Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105: 68191.
  • 90
    Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn’s disease. Arch Dis Child 1987; 62: 1237.
  • 91
    Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn’s disease. J Pediatr Gastroenterol Nutr 1993; 17: 7581.
  • 92
    Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 37380.
  • 93
    Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004; 19: 19618.
    Direct Link:
  • 94
    Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr 2006; 43: 14455.
  • 95
    Ballinger AB, Azooz O, El Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46: 694700.
  • 96
    Kelts DG, Grand RJ, Shen G, Watkins JB, Werlin SL, Boehme C. Nutritional basis of growth failure in children and adolescents with Crohn’s disease. Gastroenterology 1979; 76: 7207.
  • 97
    Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 2005; 3: 11321.
  • 98
    Daly JR, Myles AB, Bacon PA, Beardwell CG, Savage O. Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967; 26: 1825.
  • 99
    Myles AB, Bacon PA, Daly JR. Single daily dose corticosteroid treatment. Effect on adrenal function and therapeutic efficacy in various diseases. Ann Rheum Dis 1971; 30: 14953.
  • 100
    Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326: 22630.
  • 101
    Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355: 5425.
  • 102
    Desrame J, Sabate JM, Agher R, et al. Assessment of hypothalamic-pituitary-adrenal axis function after corticosteroid therapy in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 178591.
  • 103
    Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1526.
  • 104
    Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; 2: CD000952.
  • 105
    Makins R, Compston J. Prevention and treatment of osteoporosis. In: IrvingP, RamptonD, ShanahanF, eds. Clinical Dilemmas in Inflammatory Bowel Disease. Oxford: Blackwell Publishing, 2006: 2014.
  • 106
    Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353: 3628.
  • 107
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 31518.
  • 108
    Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 136673.
  • 109
    Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 164753.
  • 110
    Tursi A, Giorgetti GM, Brandimarte G, Elisei W, Aiello F. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006; 12: I2932.
  • 111
    Annese V, Latiano A, Rossi L, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am J Gastroenterol 2005; 100: 13705.
    Direct Link:
  • 112
    Darlow SJ, Mandal A, Pick B, Thomas T, Mayberry JF, Robinson RJ. The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis. Eur J Gastroenterol Hepatol 2004; 16: 11736.
  • 113
    Hanauer SB, Sparrow M. COLAL-PRED Alizyme. Curr Opin Investig Drugs 2004; 5: 11927.
  • 114
    Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 23: 143542.
  • 115
    Creed TJ, Probert CSJ. Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies. Aliment Pharmacol Ther 2007; 25: 11122.
  • 116
    Lakatos PL, Fischer S, Claes K, et al. DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn’s disease. Inflamm Bowel Dis 2006; 12: 3628.
  • 117
    Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003; 178: 33946.
  • 118
    Bebb JR, Scott BB. How effective are the usual treatments for Crohn’s disease? Aliment Pharmacol Ther 2004; 20: 1519.
  • 119
    Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn’s disease: a controlled double-blind study. Gut 1981; 22: 4049.
  • 120
    Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 37988.
  • 121
    Gross V, Andus T, Fischbach W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn’s ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol 1995; 33: 5814.
  • 122
    Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2005; 1: CD003459.
  • 123
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398405.
  • 124
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333.
  • 125
    Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn’s disease: a controlled trial. Gut 1978; 19: 60610.
  • 126
    Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2001; 1: CD002913.
  • 127
    Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 2005; 1: CD003715.
  • 128
    Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 84155.
  • 129
    Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 85661.
  • 130
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 161721.
  • 131
    Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000; 2: CD000067.
  • 132
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 162732.
  • 133
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 134
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 87685.
  • 135
    Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2006; 4: CD004826.
  • 136
    Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000; 2: CD000299.
  • 137
    Yamamoto T, Allan RN, Keighley MR. Audit of single-stage proctocolectomy for Crohn’s disease: postoperative complications and recurrence. Dis Colon Rectum 2000; 43: 24956.
  • 138
    Post S, Betzler M, Von Ditfurth B, Schurmann G, Kuppers P, Herfarth C. Risks of intestinal anastomoses in Crohn’s disease. Ann Surg 1991; 213: 3742.
  • 139
    Bruewer M, Utech M, Rijcken EJ, et al. Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohns disease. World J Surg 2003; 27: 130610.
  • 140
    Yamamoto T, Keighley MR. Factors affecting the incidence of postoperative septic complications and recurrence after strictureplasty for jejunoileal Crohn’s disease. Am J Surg 1999; 178: 2405.
  • 141
    Heimann TM, Greenstein AJ, Mechanic L, Aufses AH Jr. Early complications following surgical treatment for Crohn’s disease. Ann Surg 1985; 201: 4948.
  • 142
    Allsop JR, Lee EC. Factors which influenced postoperative complications in patients with ulcerative colitis or Crohn’s disease of the colon on corticosteroids. Gut 1978; 19: 72934.
  • 143
    Knudsen L, Christiansen L, Jarnum S. Early complications in patients previously treated with corticosteroids. Scand J Gastroenterol Suppl 1976; 37: 1238.
  • 144
    Eccles M, Clapp Z, Grimshaw J, et al. North of England evidence based guidelines development project: methods of guideline development. BMJ 1996; 312: 7602.